BACE1 and Alzheimer disease: In an animal model with systemic inflammation, the administration of a STAT3 inhibitor not only protects against microglial activation and neuroinflammation, characteristic of AD pathophysiology, but also reduces beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) protein levels [45].